Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06580106 · ClinicalTrials.gov registry record
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
A clinical trial of Leukemia, Myeloid, Acute, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 50
- Enrollment target
- 2
- Study locations
NCT06580106 is a study of Leukemia, Myeloid, Acute that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants, below the 114-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06580106, a study of Leukemia, Myeloid, Acute, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
Conditions Studied
Interventions
- OTHER Biospecimen samples
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2030-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06580106
The ClinicalTrials.gov registry entry for NCT06580106 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 114-participant average among 30 other Leukemia, Myeloid, Acute trials with a reported enrollment target (56% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Myeloid, Acute appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen samples is the first listed.
NCT06580106 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06580106 about?
NCT06580106 is a clinical study titled "Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML". The purpose of this research is to see how certain genetic variations relate to side effects and outcomes experienced while receiving treatment with azacitidine and venetoclax.
What is the current status of trial NCT06580106?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-04-09. Estimated completion is 2030-01.
What conditions does trial NCT06580106 study?
This clinical trial studies the following conditions: Leukemia, Myeloid, Acute.
What interventions are being tested in trial NCT06580106?
The interventions under investigation include: Biospecimen samples (OTHER).
Who is sponsoring clinical trial NCT06580106?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06580106 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia, Myeloid, Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RECRUITING · Phase 3
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
RECRUITING · Phase 2
-
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.